Motley Fool Asset Management LLC Acquires 266 Shares of Illumina, Inc. (NASDAQ:ILMN)

Motley Fool Asset Management LLC boosted its holdings in Illumina, Inc. (NASDAQ:ILMN) by 6.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,314 shares of the life sciences company’s stock after acquiring an additional 266 shares during the quarter. Motley Fool Asset Management LLC’s holdings in Illumina were worth $601,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ILMN. Eukles Asset Management lifted its position in shares of Illumina by 1.7% during the 3rd quarter. Eukles Asset Management now owns 5,942 shares of the life sciences company’s stock worth $816,000 after buying an additional 100 shares during the period. Clear Creek Financial Management LLC boosted its stake in shares of Illumina by 6.3% in the 4th quarter. Clear Creek Financial Management LLC now owns 1,695 shares of the life sciences company’s stock valued at $236,000 after purchasing an additional 100 shares in the last quarter. Lido Advisors LLC grew its holdings in shares of Illumina by 6.1% in the 3rd quarter. Lido Advisors LLC now owns 1,859 shares of the life sciences company’s stock worth $255,000 after purchasing an additional 107 shares during the last quarter. Quent Capital LLC increased its position in shares of Illumina by 45.2% during the 4th quarter. Quent Capital LLC now owns 363 shares of the life sciences company’s stock worth $51,000 after purchasing an additional 113 shares in the last quarter. Finally, Independent Advisor Alliance lifted its holdings in Illumina by 8.6% during the 3rd quarter. Independent Advisor Alliance now owns 1,595 shares of the life sciences company’s stock valued at $219,000 after purchasing an additional 126 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Price Performance

Shares of ILMN opened at $122.28 on Friday. The stock has a 50 day simple moving average of $131.51 and a 200 day simple moving average of $127.39. Illumina, Inc. has a 52-week low of $89.00 and a 52-week high of $213.91. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.29 and a current ratio of 1.66. The firm has a market capitalization of $19.47 billion, a PE ratio of -16.66 and a beta of 1.19.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.13. The firm had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.09 billion. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. The company’s revenue for the quarter was up 3.6% compared to the same quarter last year. During the same period in the prior year, the business earned $0.14 EPS. Sell-side analysts predict that Illumina, Inc. will post 0.91 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Jacob Thaysen bought 7,330 shares of the business’s stock in a transaction that occurred on Thursday, February 22nd. The stock was acquired at an average cost of $135.29 per share, for a total transaction of $991,675.70. Following the purchase, the chief executive officer now owns 14,861 shares of the company’s stock, valued at approximately $2,010,544.69. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.17% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on ILMN. Barclays upped their price objective on shares of Illumina from $85.00 to $100.00 and gave the stock an “underweight” rating in a research note on Wednesday, April 10th. Stephens reaffirmed an “overweight” rating and set a $170.00 price target on shares of Illumina in a report on Wednesday, April 10th. OTR Global restated a “mixed” rating on shares of Illumina in a report on Wednesday, March 20th. Royal Bank of Canada reiterated an “outperform” rating and set a $253.00 price target on shares of Illumina in a research report on Tuesday, April 9th. Finally, StockNews.com raised shares of Illumina from a “hold” rating to a “buy” rating in a report on Friday, February 16th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $167.70.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.